Clinical Trial Update: Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） [EARLY_Phase 1]

View source ↗

Summary

An early Phase 1 trial evaluating [177Lu]Lu-PSMA-137 for metastatic castration-resistant prostate cancer, with not-yet-recruiting status and sponsored by Peking…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• [177Lu]Lu-PSMA-137 (Lutetium-177 PSMA-137)

Snippet

Sponsor: Peking University First Hospital | Conditions: Prostate Cancer | EARLY_Phase 1 | Status: NOT_YET_RECRUITING